EUVIMEDEUVIMED entdecken
Crossref

Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with STEMI: design of the COPERNICAN trial

Jorge Sanz-Sánchez, Sandra Santos Martínez, Eva Rumiz González, Juan Francisco Oteo Domínguez, David Tejada Ponce, Antonio Gómez Menchero, Guillermo Sánchez Elvira, Georgina Fuertes Ferre, Fernando Rivero Crespo, Antonela Lukic Otanovic, José Díaz Fernández, Eladio Galindo Fernández und 9 weitere

Revista Española de Cardiología (English Edition) · 2026

DOI: 10.1016/j.rec.2025.05.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Española de Cardiología (English Edition), 2026. Verfasst von Jorge Sanz-Sánchez und 20 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cardiología, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiova…. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: SEINPRE, CARDIOSPAIN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND OBJECTIVES: Primary percutaneous coronary intervention (PCI) with drug-eluting stent implantation (DES) is the standard of treatment in patients presenting with ST-segment elevation myocardial infarction (STEMI). However, target lesion failure can occur due to stent underexpansion, malapposition, hypersensitivity, fracture, and neoatherosclerosis. Drug-coated balloons (DCB) represent a potential alternative supported by the concept of "leaving nothing behind." The aim is to compare a reduced stent strategy based on DCB- with DES-PCI in patients presenting with STEMI. METHODS: Prospective, pragmatic, multicenter, noninferiority, randomized clinical trial. RESULTS: A total of 1 272 patients presenting with STEMI will be randomized to any paclitaxel-DCB vs any sirolimus-DES (both with CE approval) for all culprit and nonculprit lesions during PCI. The primary endpoint will be target-lesion failure: cardiac death, target-vessel myocardial infarction, or ischemia-driven target lesion revascularization at 12-month follow-up. An independent clinical events committee masked to treatment allocation will adjudicate all suspected events. Clinical follow-up will be performed after 1 month (30 days±5 days) and 1 year (365 days±30 days). An extended follow-up at 3, 5, and 10 years is planned. CONCLUSIONS: The COPERNICAN trial will be the first randomized study comparing clinical outcomes of DCB vs DES in STEMI patients. CLINICALTRIALS: gov: NCT06353594.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsPercutaneous Coronary InterventionST Elevation Myocardial InfarctionAgedFemaleHumansMaleMiddle AgedCoronary AngiographyFollow-Up StudiesPaclitaxelProspective StudiesProsthesis DesignSirolimusTreatment OutcomeRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

BFABalón farmacoactivoDCBDESDrug-coated balloonDrug-eluting stent implantationIAMCESTInfarto agudo de miocardio con elevación del segmento STSFAST-segment elevation myocardial infarctionSTEMIStent farmacoactivo

Substanzen

PaclitaxelSirolimus

Autor:innen und Institutionen

  • Servicio de Cardiología, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
  • Servicio de Cardiología, Hospital General Universitario de Elche, Elche, Alicante, Spain.
  • Servicio de Cardiología, Hospital General Universitario de Valencia, Valencia, Spain.
  • Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
  • Servicio de Cardiología, Hospital Provincial de Castellón, Castellón, Spain.
  • Servicio de Cardiología, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain.

Förderung

  • SEINPRE
  • CARDIOSPAIN

Zitieren

APA

Sanz-Sánchez, J., Santos Martínez, S., Rumiz González, E., Oteo Domínguez, J. F., Tejada Ponce, D., Gómez Menchero, A., Sánchez Elvira, G., Fuertes Ferre, G., Rivero Crespo, F., Lukic Otanovic, A., Díaz Fernández, J., Galindo Fernández, E., Urbano Carrillo, C., Salvatella Giralt, N., Torres Sánchez, M., García Touchard, A., Ibáñez Cabeza, B., Stefanini, G., Alfonso Manterola, F., …, & Amat-Santos, I. J. (2026). Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with STEMI: design of the COPERNICAN trial. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2025.05.005

Vancouver

Sanz-Sánchez J, Santos Martínez S, Rumiz González E, Oteo Domínguez JF, Tejada Ponce D, Gómez Menchero A, et al. Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with STEMI: design of the COPERNICAN trial. Revista Española de Cardiología (English Edition). 2026. doi:10.1016/j.rec.2025.05.005

BibTeX
@article{SanzSnchez2026,
  author = {Sanz-Sánchez, Jorge and Santos Martínez, Sandra and Rumiz González, Eva and Oteo Domínguez, Juan Francisco and Tejada Ponce, David and Gómez Menchero, Antonio and Sánchez Elvira, Guillermo and Fuertes Ferre, Georgina and Rivero Crespo, Fernando and Lukic Otanovic, Antonela and Díaz Fernández, José and Galindo Fernández, Eladio and Urbano Carrillo, Cristóbal and Salvatella Giralt, Neus and Torres Sánchez, Mauricio and García Touchard, Arturo and Ibáñez Cabeza, Borja and Stefanini, Giulio and Alfonso Manterola, Fernando and García García, Héctor and Amat-Santos, Ignacio J},
  title = {Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with STEMI: design of the COPERNICAN trial},
  journal = {Revista Española de Cardiología (English Edition)},
  year = {2026},
  doi = {10.1016/j.rec.2025.05.005}
}
Kostenlos starten →